glp-1 colorectal cancer risk study november 2025 Association between receptor agonists as a class and risk: a meta-analysis of retrospective cohort studies | BMC Gastroenterology glp-1 colorectal cancer risk study

We dont prescribe peptides casually for performance we build protocols that are safe, effective, and appropriate for your training load

It works as both a GLP-1 agonist and a GIP receptor agonist, which helps explain why patients lose more weight compared to many older medications

Focus on whole, nutrient-dense options instead

About the company Nutrabay is India's #1 trusted and fastest growing nutrition brand with a wide range of products for health, wellness, sports supplements, fitness & bodybuilding

One analysis found those who took GLP-1 medications were 30% less likely to develop breast cancer, the worlds most common form of the disease, compared with those not taking weight-loss drugs